Study protocol for a randomised controlled trial evaluating the effects of the orexin receptor antagonist suvorexant on sleep architecture and delirium in the intensive care unit.

ABSTRACT:

Introduction

Insomnia frequently occurs in patients admitted to an intensive care unit (ICU). Sleep-promoting agents may reduce rapid eye movement sleep and have deliriogenic effects. Suvorexant (Belsomra) is an orexin receptor antagonist with Food and Drug Administration (FDA) approval for the treatment of adult insomnia, which improves sleep onset and maintenance as well as subjective measures of quality of sleep. This trial will evaluate the efficacy of postoperative oral suvorexant treatment on night-time wakefulness after persistent sleep onset as well as the incidence and duration of delirium among adult cardiac surgical patients.

Methods and analysis

In this single-centre, randomised, double-blind, placebo-controlled trial, we will enrol 120 patients, aged 60 years or

SUBMITTER: Azimaraghi O 

PROVIDER: S-EPMC7371384 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature